PCI Biotech Holding ASA (LON:0JGL)

Market Cap	683.62K -79.3%
Revenue (ttm)	338.24K -21.9%
Net Income	-1.48M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,801
Average Volume	68,049
Open	0.2430
Previous Close	0.2380
Day's Range	0.2120 - 0.2470
52-Week Range	0.1305 - 2.0000
Beta	1.23
RSI	49.97
Earnings Date	Feb 17, 2026

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JGL

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.

Financial numbers in NOK